1 40 1 Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. URL Address <a href="http://doi.org/10.1002/jmri.27731" target="_blank" rel="noreferrer noopener">http://doi.org/10.1002/jmri.27731</a> ISSN 1522-2586 1053-1807 Search for Full-text Locate full-text within NEOMED Library's e-journal collections <a href="http://neomed.idm.oclc.org/login?url=http://doi.org/10.1002/jmri.27731" target="_blank" rel="noreferrer noopener">NEOMED Full-text Holding (if available) - Proxy DOI: 10.1002/jmri.27731</a> <p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p> Update Year & Number June 2021 List NEOMED College NEOMED College of Medicine NEOMED Department Department of Radiology Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Dose-Lowering in Contrast-Enhanced MRI of the Central Nervous System: A Retrospective, Parallel-Group Comparison Using Gadobenate Dimeglumine. Publisher An entity responsible for making the resource available Journal Of Magnetic Resonance Imaging : JMRI Date A point or period of time associated with an event in the lifecycle of the resource 2021 2021-05-20 Subject The topic of the resource comparative studies; contrast efficacy; gadobenate dimeglumine; GBCA safety Creator An entity primarily responsible for making the resource DeLano MC; Spampinato MV; Chang EY; Barr RG; Lichtenstein RJ; Colosimo C; Vymazal J; Wen Z; Lin DDM; Kirchin MA; Pirovano G Description An account of the resource BACKGROUND: Concerns over gadolinium (Gd) retention encourage the use of lower Gd doses. However, lower Gd doses may compromise imaging performance. Higher relaxivity gadobenate may be suited to reduced dose protocols. PURPOSE: To compare 0.05 mmol/kg and 0.1 mmol/kg gadobenate in patients undergoing enhanced MRI of the central nervous system (CNS). STUDY TYPE: Retrospective, multicenter. POPULATION: Three hundred and fifty-two patients receiving 0.05 (n = 181) or 0.1 (n = 171) mmol/kg gadobenate. FIELD STRENGTH/SEQUENCES: 1.5 T and 3.0 T/precontrast and postcontrast T1-weighted spin echo/fast spin echo (SE/FSE) and/or gradient echo/fast field echo (GRE/FFE); precontrast T2-weighted FSE and T2-FLAIR. ASSESSMENT: Images of patients with extra-axial lesions at 1.5 T or any CNS lesion at 3.0 T were reviewed by three blinded, independent neuroradiologists for qualitative (lesion border delineation, internal morphology visualization, contrast enhancement; scores from 1 = poor to 4 = excellent) and quantitative (lesion-to-brain ratio [LBR], contrast-to-noise ratio [CNR]; SI measurements at regions-of-interest on lesion and normal parenchyma) enhancement measures. Noninferiority of 0.05 mmol/kg gadobenate was determined for each qualitative endpoint if the lower limit of the 95% confidence interval (CI) for the difference in precontrast + postcontrast means was above a noninferiority margin of -0.4. STATISTICAL TESTS: Student's t-test for comparison of mean qualitative endpoint scores, Wilcoxon signed rank test for comparison of LBR and CNR values; Wilcoxon rank sum test for comparison of SI changes. Tests were significant for P < 0.05. RESULTS: The mean change from precontrast to precontrast + postcontrast was significant for all endpoints. Readers 1, 2, and 3 evaluated 304, 225, and 249 lesions for 0.05 mmol/kg gadobenate, and 382, 309, and 298 lesions for 0.1 mmol/kg gadobenate. The lower limit of the 95% CI was above -0.4 for all comparisons. Significantly, higher LBR and CNR was observed with the higher dose. DATA CONCLUSION: 0.05 mmol/kg gadobenate was noninferior to 0.1 mmol/kg gadobenate for lesion visualization. EVIDENCE LEVEL: 2 TECHNICAL EFFICACY: Stage 3. Identifier An unambiguous reference to the resource within a given context <a href="http://doi.org/10.1002/jmri.27731" target="_blank" rel="noreferrer noopener">10.1002/jmri.27731</a> Rights Information about rights held in and over the resource Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s). Format The file format, physical medium, or dimensions of the resource journalArticle 2021 Barr RG Chang EY Colosimo C Comparative Studies contrast efficacy DeLano MC Department of Radiology gadobenate dimeglumine GBCA safety Journal of magnetic resonance imaging : JMRI journalArticle June 2021 List Kirchin MA Lichtenstein RJ Lin DDM NEOMED College of Medicine Pirovano G Spampinato MV Vymazal J Wen Z